Associated Papers
Molecular determinants of survival in metastatic uveal melanoma: The impact of SF3B1 mutations.
Del Carpio LP et al.
European Journal of Cancer (oxford, England : 1990), 2025
Genotyping as Part of Routine Clinical Care-The Outcomes for a Large Paediatric Vascular Anomaly Cohort.
O'Sullivan S et al.
American Journal of Medical Genetics. Part A, 2025
Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma.
Terai M et al.
Journal of Clinical Medicine, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis.
Lamas-Francis D et al.
Cancers, 2024
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.
Elbatsh AMO et al.
Nature Cancer, 2024
Somatic GJA4 mutation in intracranial extra-axial cavernous hemangiomas.
Huo R et al.
Stroke and Vascular Neurology, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Next-generation sequencing of uveal melanoma with clinical and histological correlations: Prognostic value of new mutations in the PI3K/AKT/mTOR pathway.
Pérez-Pérez M et al.
Clinical & Experimental Ophthalmology, 2023
Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.
Wang HY et al.
Cancer Cell International, 2023
Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman.
Khatri S et al.
Cureus, 2023
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients.
García-Mulero S et al.
Oncoimmunology, 2023
Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genetics, 2021
Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma.
Terai M et al.
Cancers, 2021
Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.
Zhou J et al.
Nature Genetics, 2021
Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
Nell RJ et al.
Bmc Cancer, 2021
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors.
Jansen P et al.
Frontiers in Genetics, 2021
Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment.
Larribère L et al.
Cancers, 2020
GNA11 Mutation as a Cause of Sturge-Weber Syndrome: Expansion of the Phenotypic Spectrum of Gα/11 Mosaicism and the Associated Clinical Diagnoses.
Polubothu S et al.
The Journal of Investigative Dermatology, 2020
Segmental congenital hemangiomas: Three cases of a rare entity.
Smith RJ et al.
Pediatric Dermatology, 2020
High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: a histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms.
Liau JY et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2019
Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G et al.
Investigative Ophthalmology & Visual Science, 2019
GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas.
Francis JH et al.
Ophthalmology, 2019
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S et al.
Cancer, 2019
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
Lier A et al.
Jco Precision Oncology, 2018
The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
Ominato J et al.
Applied Immunohistochemistry & Molecular Morphology : Aimm, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Bailey MH et al.
Cell, 2018
GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome.
Abdel Karim N et al.
Case Reports in Oncological Medicine, 2018
SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
Mori T et al.
Investigative Ophthalmology & Visual Science, 2017
Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
Busser B et al.
Biomed Research International, 2017
Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.
Funk T et al.
Jama Dermatology, 2016
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P et al.
Oncotarget, 2016
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE et al.
Oncotarget, 2015
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R et al.
Bmc Cancer, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.
O'Hayre M et al.
Nature Reviews. Cancer, 2013